Jinsong Jia

6PUBLICATIONS
16CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedPredictive and prognostic markersHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 22, 2024
Venetoclax and Hypomethylating Agent in Previously Untreated Higher-Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real-World Study.

Jing Wang, Zhijian Fang, Siyi Yang

|Apr 27, 2024
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.

Fei-Fei Tang, Wen-Bing Duan, Xiao-Hong Liu

|Jul 08, 2023
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.

Hui Liu, Linghui Xia, Jianyu Weng

|Jun 23, 2023
Decitabine in patients with myelodysplastic syndromes: A multi-center, open-label, dose comparison trial.

Hui Liu, Hao Jiang, Hongyan Tong

|Apr 24, 2023
COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.

Xiaolu Zhu, Qian Jiang, Jin Lu

|Aug 18, 2021
PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort study.

Fei-Fei Tang, Sheng-Ye Lu, Xiao-Su Zhao

Pageof 1

Frequent Collaborators

3 joint publications

Qian Jiang

3 joint publications

Xiaojun Huang

3 joint publications

Hao Jiang

3 joint publications

Jing Wang